Approaches to Managing Autoimmune Cytopenias in Novel Immunological Disorders with Genetic Underpinnings Like Autoimmune Lymphoproliferative Syndrome

Frontiers in Pediatrics

Volumn 3, Issue , 2015, Pages

  Rao, V Koneti ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

autoimmune diseases; autoimmune lymphoproliferative syndrome; cytopenias; genetic disease; lymphoproliferative disorders

Indexed keywords

EID: 84955475007     PISSN: None     EISSN: 22962360     Source Type: Journal    
DOI: 10.3389/fped.2015.00065     Document Type: Article

References (32)

1. Sneller MC Straus SE Jaffe ES Jaffe JS Fleisher TA Stetler-Stevenson M et al. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest (1992) 90(2):334–41.10.1172/JCI1158671386609
2. Jackson CE Fischer RE Hsu AP Anderson SM Choi Y Wang J et al. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. Am J Hum Genet (1999) 64(4):1002–14.10.1086/30233310090885
3. Rieux-Laucat F Le Deist F Hivroz C Roberts IA Debatin KM Fischer A et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science (1995) 268(5215):1347–9.10.1126/science.75391577539157
4. Dowdell KC Niemela JE Price S Davis J Hornung RL Oliveira JB et al. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. Blood (2010) 115(25):5164–9.10.1182/blood-2010-01-26314520360470
5. Holzelova E Vonarbourg C Stolzenberg MC Arkwright PD Selz F Prieur AM et al. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med (2004) 351(14):1409–18.10.1056/NEJMoa04003615459302
6. Rudman Spergel A Walkovich K Price S Niemela JE Wright D Fleisher TA et al. Autoimmune lymphoproliferative syndrome misdiagnosed as hemophagocytic lymphohistiocytosis. Pediatrics (2013) 132(5):e1440–4.10.1542/peds.2012-274824101757
7. Neven B Magerus-Chatinet A Florkin B Gobert D Lambotte O De Somer L et al. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood (2011) 118(18):4798–807.10.1182/blood-2011-04-34764121885602
8. Price S Shaw PA Seitz A Joshi G Davis J Niemela JE et al. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood (2014) 123(13):1989–99.10.1182/blood-2013-10-53539324398331
9. Neven B Bruneau J Stolzenberg MC Meyts I Magerus-Chatinet A Moens L et al. Defective anti-polysaccharide response and splenic marginal zone disorganization in ALPS patients. Blood (2014) 124(10):1597–609.10.1182/blood-2014-02-55383424970930
10. Rao VK Oliveira JB. How I treat autoimmune lymphoproliferative syndrome. Blood (2011) 118(22):5741–51.10.1182/blood-2011-07-32521721885601
11. Teachey DT Lambert MP. Diagnosis and management of autoimmune cytopenias in childhood. Pediatr Clin North Am (2013) 60(6):1489–511.10.1016/j.pcl.2013.08.009
12. Rao VK Price S Perkins K Aldridge P Tretler J Davis J et al. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer (2009) 52(7):847–52.10.1002/pbc.2196519214977
13. Rao VK Dugan F Dale JK Davis J Tretler J Hurley JK et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol (2005) 129(4):534–8.10.1111/j.1365-2141.2005.05496.x15877736
14. Rao VK Straus SE. Causes and consequences of the autoimmune lymphoproliferative syndrome. Hematology (2006) 11(1):15–23.10.1080/10245330500329094
15. Teachey DT Obzut DA Axsom K Choi JK Goldsmith KC Hall J et al. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood (2006) 108(6):1965–71.10.1182/blood-2006-01-01012416757690
16. Teachey DT Seif AE Grupp SA. Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS). Br J Haematol (2010) 148(2):205–16.10.1111/j.1365-2141.2009.07991.x19930184
17. Cines DB Bussel JB Liebman HA Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood (2009) 113(26):6511–21.10.1182/blood-2009-01-12915519395674
18. Cines DB Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood (2005) 106(7):2244–51.10.1182/blood-2004-12-4598
19. Oliveira JB Bleesing JJ Dianzani U Fleisher TA Jaffe ES Lenardo MJ et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood (2010) 116(14):e35–40.10.1182/blood-2010-04-28034720538792
20. Moraitis AG Freeman LA Shamburek RD Wesley R Wilson W Grant CM et al. Elevated interleukin-10: a new cause of dyslipidemia leading to severe HDL deficiency. J Clin Lipidol (2015) 9(1):81–90.10.1016/j.jacl.2014.09.01425670364
21. Caminha I Fleisher TA Hornung RL Dale JK Niemela JE Price S et al. Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol (2010) 125(4):946–949e946.10.1016/j.jaci.2009.12.983
22. Magerus-Chatinet A Stolzenberg MC Loffredo MS Neven B Schaffner C Ducrot N et al. FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. Blood (2009) 113(13):3027–30.10.1182/blood-2008-09-17963019176318
23. Teachey DT Greiner R Seif A Attiyeh E Bleesing J Choi J et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol (2009) 145(1):101–6.10.1111/j.1365-2141.2009.07595.x19208097
24. Neunert CE Buchanan GR Imbach P Bolton-Maggs PH Bennett CM Neufeld E et al. Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood (2013) 121(22):4457–62.10.1182/blood-2012-12-46637523550040
25. Calvo KR Price S Braylan RC Oliveira JB Lenardo M Fleisher TA et al. JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities. Blood (2015) 125(18):2753–8.10.1182/blood-2014-11-56791725691160
26. Kuehn HS Ouyang W Lo B Deenick EK Niemela JE Avery DT et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science (2014) 345(6204):1623–7.10.1126/science.125590425213377
27. Milner JD Vogel TP Forbes L Ma CA Stray-Pedersen A Niemela JE et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood (2015) 125(4):591–9.10.1182/blood-2014-09-60276325359994
28. Lucas CL Kuehn HS Zhao F Niemela JE Deenick EK Palendira U et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat Immunol (2014) 15(1):88–97.10.1038/ni.277124165795
29. Li FY Chaigne-Delalande B Su H Uzel G Matthews H Lenardo MJ. XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus. Blood (2014) 123(14):2148–52.10.1182/blood-2013-11-53868624550228
30. Seidel MG. Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment. Blood (2014) 124(15):2337–44.10.1182/blood-2014-06-58326025163701
31. Revel-Vilk S Fischer U Keller B Nabhani S Gámez-Díaz L Rensing-Ehl A et al. Autoimmune lymphoproliferative syndrome-like disease in patients with LRBA mutation. Clin Immunol (2015) 159(1):84–92.10.1016/j.clim.2015.04.00725931386
32. Rensing-Ehl A Warnatz K Fuchs S Schlesier M Salzer U Draeger R et al. Clinical and immunological overlap between autoimmune lymphoproliferative syndrome and common variable immunodeficiency. Clin Immunol (2010) 137(3):357–65.10.1016/j.clim.2010.08.00820832369